It highlights advances in understanding disease mechanisms, conditions for trial readiness, and long-term outcome collection. Early access, regulatory hurdles, and the importance of registries are explained. Overall, molecular therapies offer hope but require careful management of expectations, infrastructure, and collaboration among healthcare providers, patients, and regulators.